Domains targeting keyword lung tests

Learn more about Activase® (Alteplase) for Acute Ischemic Stroke Treatment. Indications Activase (alteplase) is indicated for the treatment of acute ischemic stroke. Exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment. Initiate treatment as soon as possible but within 3 hours after symptom onset. Activase is indicated for use in acute myocardial infarction (AMI) for the reduction of mortality and reduction of the incidence of heart failure. Limitation of Use: The risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose AMI puts them at low risk for death or heart failure. Activase is indicated for the lysis of acute massive pulmonary embolism (PE), defined as: • Acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments. • Acute pulmonary emboli accompanied by unstable hemodynamics, e.g.,failure to maintain blood pressure without supportive measures. Important Safety Information Contraindications Do not administer Activase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit: current intracranial hemorrhage (ICH); subarachnoid hemorrhage; active internal bleeding; recent (within 3months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding; bleeding diathesis; and current severe uncontrolled hypertension. Do not administer Activase to treat acute myocardial infarction or pulmonary embolism in the following situations in which the risk of bleeding is greater than the potential benefit: active internal bleeding; history of recent stroke; recent (within 3months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding; bleeding diathesis; and current severe uncontrolled hypertension. Warnings and Precautions Bleeding Activase can cause significant, sometimes fatal, internal or external bleeding, especially at arterial and venous puncture sites.Avoid intramuscular injections and trauma to the patient. Fatal cases of hemorrhage associated with traumatic intubation in patients administered Activase have been reported. Heparin, aspirin, or Activase may cause bleeding complications; therefore carefully monitor for bleeding. If serious bleeding occurs, terminate the Activase infusion. Orolingual Angioedema Monitor patients during and for several hours after infusion for orolingual angioedema. If angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy. Cholesterol Embolization Cholesterol embolism, sometimes fatal, has been reported rarely in patients treated with thrombolytic agents. Reembolization of Deep Venous Thrombi during Treatment for Acute Massive Pulmonary Embolism Consider the possible risk of reembolization due to the lysis of underlying deep venous thrombi patients with acute massive PE Coagulation Tests May be Unreliable during Activase Therapy Coagulation tests and/or measures of fibrinolytic activity may be unreliable during Activase therapy. Adverse Reactions The most frequent adverse reaction associated with Activase therapy is bleeding. Allergic‑type reactions, e.g.,anaphylactoid reaction, laryngeal edema, orolingual angioedema, rash, and urticaria have been reported.

The respiratory lab offers respiratory function tests to patients in South-East Queensland and services the Mater Private Hospital.

Our services include cardiology, respiratory medicine, and cardiothoracic surgery and we are the country’s main heart and lung transplant centre.

Learn about HEMLIBRA® (emicizumab-kxwh), a hemophilia A treatment now approved for people with hemophilia A with factor VIII inhibitors. See BOXED WARNING. What is HEMLIBRA? HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors. What is the most important information I should know about HEMLIBRA? HEMLIBRA increases the potential for your blood to clot. Discontinue prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent, and the dose and schedule you should use. HEMLIBRA may cause the following serious side effects when used with aPCC (FEIBA®), including: Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the signs and symptoms of TMA during or after treatment with HEMLIBRA. Blood clots (thrombotic events). Blood clots may form in blood vessels in your arm, leg, lung or head. Get medical help right away if you have any of the signs or symptoms of blood clots during or after treatment with HEMLIBRA. If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total. How should I use Hemlibra? See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes. HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care. What are the other possible side effects of HEMLIBRA? The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain. These are not all of the possible side effects of HEMLIBRA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see the HEMLIBRA full Prescribing Information and Medication Guide for more important safety information including Serious Side Effects.

ndd Medical offers innovative, easy-to-use pulmonary function testing instruments that help clinicians diagnose and treat lung disease with greater precision. Your choice is an EasyOne.

We have specialists offering all kind of lung care treatments & tests such as asthma, sleep disorders, lung cancer & pulmonary allergy in Fort Myers.

Cystic Fibrosis nutrition and disease management and tracking. Patients with CF can plan, track, and report their nutrition, daily diet intake, medical tests, medication, create meal plans, recipes, online diary, and more. CF patients can also safely connect to their healthcare providers and peers.

Our services include cardiology, respiratory medicine, and cardiothoracic surgery and we are the country's main heart and lung transplant centre.

Health Scan Imaging offers you exclusive access to the world’s newest and most advanced multi-slice, multichannel, three-dimensional CT and MRI scanners. We specialize in early detection of potentially life-threatening disease in adults who feel well and who are without symptoms. Our ultra-sensitive, next-generation technology,combined with the recognized professional expertise of our fellowship-trainedradiologists, enables Health Scan Imaging to give you the very best science has tooffer for early disease detection.